Effect of Deutetrabenazine on Quality of Life in Patients With Tardive Dyskinesia in AIM-TD, a 12-Week Double-Blind, Placebo-Controlled Study

This poster was presented at the 30th annual  Psych Congress, held Sept. 16-19, 2017, in New Orleans, Louisiana.

Introduction: Tardive dyskinesia (TD) is a movement disorder that can be debilitating, add to the stigma of a psychiatric disorder, and negatively impact quality of life (QoL) for patients already stigmatized by mental illness. The modified Craniocervical Dystonia Questionnaire (mCDQ-24) is a QoL questionnaire adapted for use in patients with TD. A reduction in score indicates improvement.

Objective: To assess the effect of deutetrabenazine on QoL of TD patients in the AIM-TD study as measured by mCDQ-24. Methods: Patients were randomized 1:1:1:1 to receive one of three fixed-dose regimens of deutetrabenazine (12 mg/day, 24 mg/day, or 36 mg/day) or placebo. Change in mCDQ-24 score from baseline to Week 12 was analyzed.

Results: The mean baseline mCDQ-24 scores were similar between patients in different treatment groups. At Week 12, there was a clinically meaningful least-squares mean treatment difference comparing deutetrabenazine 36 mg/day (-4.4, P=0.123; n=55) and 24 mg/day (-3.5, P=0.242; n=49) with placebo (n=58). Four of five mCDQ-24 subdomains evaluated improved with deutetrabenazine 36 mg/day versus placebo at Week 12 [Activities of Daily Living: -5.0; Pain: -9.5; Social: -6.8; Stigma: -3.4]. Deutetrabenazine 24 mg/day also improved the Pain (-9.1) and Stigma (-7.9) subdomains versus placebo. Emotional well-being did not improve with treatment. Deutetrabenazine was generally well tolerated.

Conclusions: Treatment with deutetrabenazine 36 mg/day improved QoL of patients with TD, as shown by reductions of scores in most mCDQ-24 subdomains. Improvements in key subdomains such as Pain and Stigma were seen with both 24 and 36 mg/day doses.